Cogent Biosciences Inc

NASDAQ COGT

Data sourced from

and

Download Data

Cogent Biosciences Inc Debt to Tangible Net Worth Ratio for the Trailing 12 Months (TTM) ending March 31, 2024

Cogent Biosciences Inc Debt to Tangible Net Worth Ratio is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The debt to tangible net worth ratio measures the level of debt relative to a company's tangible net worth. It is calculated by dividing total debt by the difference between shareholders' equity and intangible assets (such as goodwill). This ratio provides insights into the company's financial leverage, excluding intangible assets. A higher ratio suggests a higher level of debt burden in relation to tangible net worth.

NASDAQ: COGT

Cogent Biosciences Inc

CEO	Mr. Andrew R. Robbins M.B.A.
IPO Date	March 29, 2018
Location	United States
Headquarters	200 Cambridge Park Drive, Cambridge, MA, United States, 02140
Employees	164
Sector	Healthcare
Industry	Biotechnology

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Key trends